HealthWell Foundation — Renal Cell Carcinoma Fund

Copay assistance fund status, eligibility, and covered drugs — for patient access and billing teams.

Maximum award Up to $8,000 · Income ≤500% FPL · Covers drug cost only — administration billed separately

OPEN
Status verified June 11, 2026 · Source: HealthWell Foundation fund page ↗

Fund facts

Published terms from the foundation. Per-patient eligibility and amounts are confirmed at application.

Assistance type
Copay Grant
Maximum award
Up to $8,000
What it covers
Covers drug cost only — administration billed separately
Income limit
≤500% FPL
Insurance
commercial medicare no medicaid
Diagnosis required
Renal Cell Carcinoma (confirmed diagnosis)
Residency
US resident
ICD-10
C64 C64.1 C64.2 C64.9
Processing time
5–10 business days
Renewal
annual reapplication
Fund availability depends on donations. May close and reopen periodically.

Covered drugs in our billing library

Drugs whose J-codes this fund matches. Each links to its billing & coding reference.

Also matches J-codes not yet in our drug library: J9023

Published formulary

The foundation's own covered-medication list for this fund (66 drugs). Confirm coverage of your exact NDC at application.

Show all 66 covered medications
  • Adriamycin
  • Afinitor
  • Aldesleukin
  • Alymsys
  • Atezolizumab
  • Avastin
  • Avelumab
  • Axitinib
  • Bavencio
  • Belzutifan
  • Bevacizumab
  • Bevacizumab-adcd
  • Bevacizumab-awwb
  • Bevacizumab-bvzr
  • Bevacizumab-maly
  • Bevacizumab-nwgd
  • Cabometyx
  • Cabozantinib
  • Capecitabine
  • Carboplatin
  • Cisplatin
  • Depo Provera
  • Doxorubicin Hydrochloride
  • Enbumyst
  • Erlotinib Hydrochloride
  • Everolimus
  • Floxuridine
  • Fluorouracil
  • Fotivda
  • Gemcitabine
  • Inlyta
  • Ipilimumab
  • Jobevne
  • Keytruda
  • Keytruda Qlex
  • Lenvatinib
  • Lenvima
  • Medroxyprogesterone Acetate
  • Mvasi
  • Nexavar
  • Nivolumab
  • Nivolumab And Hyaluronidase-nvhy
  • Opdivo
  • Opdivo Qvantig
  • Paclitaxel
  • Pazopanib
  • Pembrolizumab
  • Proleukin
  • Rapamune
  • Sirolimus
  • Sorafenib Tosylate
  • Sunitinib Malate
  • Sutent
  • Tarceva
  • Tecentriq
  • Temsirolimus
  • Tivozanib
  • Torisel
  • Vegzelma
  • Vinblastine Sulfate
  • Votrient
  • Welireg
  • Xeloda
  • Yervoy
  • Zirabev
  • Zortress

This fund is open — what will your patient owe?

Run a Medicare estimate for a covered drug in about a minute. The fund's award caps against the patient share CareCost calculates.

Common questions

Is the HealthWell Foundation Renal Cell Carcinoma fund open?

As of June 11, 2026, the HealthWell Foundation Renal Cell Carcinoma fund is OPEN and accepting applications. Verify at time of service: 800-675-8416.

How much assistance does the Renal Cell Carcinoma fund provide?

Up to $8,000. Covers drug cost only — administration billed separately

What are the income limits for the Renal Cell Carcinoma fund?

Household income must be ≤500% FPL. US resident.

What insurance does the Renal Cell Carcinoma fund accept?

Accepted: commercial, medicare. Not eligible: medicaid.

How long does the Renal Cell Carcinoma fund take to process an application?

The foundation's published processing time is 5–10 business days. Renewal: annual reapplication.

Patient or caregiver? Show this page to your infusion center's financial counselor — they can check what you'd qualify for and apply on your behalf, or call HealthWell Foundation at 800-675-8416.